April 10, 2018 / 12:44 PM / 2 months ago

BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout

April 10 (Reuters) - Selecta Biosciences Inc:

* 212, IN DEVELOPMENT FOR CHRONIC SEVERE GOUT, AT PANLAR 2018 CONGRESS

* 212 PRODUCT PROFILE MAY PROVIDE BETTER AND MORE SUSTAINED SERUM URIC ACID CONTROL

* 212 GENERALLY WELL TOLERATED AT CLINICALLY ACTIVE DOSES FOLLOWING REPEATED ADMINISTRATIONS IN ONGOING PHASE 2 TRIAL

* 212 IS EXPECTED TO START LATER IN 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below